YM155 sensitizes ovarian cancer cells to cisplatin inducing apoptosis and tumor regression

Gynecologic Oncology

Volumn 132, Issue 1, 2014, Pages 211-220

  Mir, Roser ^a   Stanzani, Elisabetta ^a   Martinez Soler, Fina ^a   Villanueva, Alberto ^b   Vidal, August ^a   Condom, Enric ^a   Ponce, Jordi ^c   Gil, Joan ^a   Tortosa, Avelina ^a   Giménez Bonafé, Pepita ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Apoptosis; Chemoresistance; Cisplatin; Ovarian cancer; Survivin; YM155

Indexed keywords

CISPLATIN; MESSENGER RNA; SEPANTRONIUM BROMIDE; SURVIVIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER REGRESSION; CANCER SIZE; CELL CYCLE; CELL VIABILITY; CELLULAR DISTRIBUTION; CHEMOSENSITIZATION; CONTROLLED STUDY; DNA DAMAGE; DRUG EFFICACY; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VIVO STUDY; M PHASE CELL CYCLE CHECKPOINT; MOUSE; NONHUMAN; OVARY CANCER; PRIMARY CELL CULTURE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; XENOGRAFT;

ANNEXIN V; ANV; APOPTOSIS; ASCITES; CASPASE INHIBITOR Q-VD-OPH; CDDP; CHEMORESISTANCE; CI; CISPLATIN; COMBINATION INDEX; DOUBLE-STRAND BREAKS; DSB; EOC; EPITHELIAL OVARIAN CANCER; FBS; FETAL BOVINE SERUM; H; HOUR; IAP; INHIBITOR OF APOPTOSIS PROTEIN; IP; LASC; MLPA; MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION; OVARIAN CANCER; OVCA; PBS; PHOSPHATE-BUFFERED SALINE; PROPIDIUM IODIDE; QVD; REAL TIME POLYMERASE CHAIN REACTION; RT-PCR; SURVIVIN; YM155;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CISPLATIN; DISEASE PROGRESSION; DNA DAMAGE; FEMALE; HUMANS; IMIDAZOLES; INHIBITOR OF APOPTOSIS PROTEINS; NAPHTHOQUINONES; OVARIAN NEOPLASMS;

EID: 84892796428     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.11.013     Document Type: Article

References (33)

1. G.H. Eltabbakh, and C.S. Awtrey Current treatment for ovarian cancer Expert Opin Pharmacother 2 2001 109 124
2. D.C. Altieri Survivin, cancer networks and pathway-directed drug discovery Nat Rev Cancer 8 2008 61 70
3. H. Yamamoto, C.Y. Ngan, and M. Monden Cancer cells survive with survivin Cancer Sci 99 2008 1709 1714
4. C. Adida, D. Berrebi, M. Peuchmaur, M. Reyes-Mugica, and D.C. Altieri Anti-apoptosis gene, survivin, and prognosis of neuroblastoma Lancet 351 1998 882 883
5. M.R. Nasr, and O. El-Zammar Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions Am J Dermatopathol 30 2008 117 122
6. C. Cohen, C.M. Lohmann, G. Cotsonis, D. Lawson, and R. Santoianni Survivin expression in ovarian carcinoma: correlation with apoptotic markers and prognosis Mod Pathol 16 2003 574 583
7. R. Mir, A. Tortosa, F. Martinez-Soler, A. Vidal, E. Condom, and A. Perez-Perarnau et al. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells Int J Cancer 132 2013 1525 1536
8. D.C. Altieri Validating survivin as a cancer therapeutic target Nat Rev Cancer 3 2003 46 54
9. H.N. Zhen, X. Zhang, P.Z. Hu, T.T. Yang, Z. Fei, and J.N. Zhang et al. Survivin expression and its relation with proliferation, apoptosis, and angiogenesis in brain gliomas Cancer 104 2005 2775 2783
10. T. Nomura, M. Yamasaki, Y. Nomura, and H. Mimata Expression of the inhibitors of apoptosis proteins in cisplatin-resistant prostate cancer cells Oncol Rep 14 2005 993 997
11. J. Xing, C.R. Jia, Y. Wang, J. Guo, and Y. Cai Effect of shRNA targeting survivin on ovarian cancer J Cancer Res Clin Oncol 138 2012 1221 1229
12. M. Pennati, G. Colella, M. Folini, L. Citti, M.G. Daidone, and N. Zaffaroni Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis J Clin Invest 109 2002 285 286
13. N. Zaffaroni, and M.G. Daidone Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions Drug Resist Updat 5 2002 65 72
14. A. Felisiak-Golabek, A. Rembiszewska, I.K. Rzepecka, L. Szafron, R. Madry, and M. Murawska et al. Nuclear survivin expression is a positive prognostic factor in taxane-platinum-treated ovarian cancer patients J Ovarian Res 4 2011 20
15. Z. Liguang, L. Peishu, M. Hongluan, J. Hong, W. Rong, and M.S. Wachtel et al. Survivin expression in ovarian cancer Exp Oncol 29 2007 121 125
16. T. Nakahara, A. Kita, K. Yamanaka, M. Mori, N. Amino, and M. Takeuchi et al. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts Cancer Res 67 2007 8014 8021
17. T. Yamauchi, N. Nakamura, M. Hiramoto, M. Yuri, H. Yokota, and M. Naitou et al. Sepantronium bromide (YM155) induces disruption of the ILF3/p54(nrb) complex, which is required for survivin expression Biochem Biophys Res Commun 425 2012 711 716
18. N. Nakamura, T. Yamauchi, M. Hiramoto, M. Yuri, M. Naito, and M. Takeuchi et al. Interleukin enhancer-binding factor 3/NF110 is a target of YM155, a suppressant of survivin Mol Cell Proteomics 11 M111 2012 013243
19. T. Nakahara, A. Kita, K. Yamanaka, M. Mori, N. Amino, and M. Takeuchi et al. Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models Cancer Sci 102 2011 614 621
20. A. Kita, T. Nakahara, K. Yamanaka, K. Nakano, M. Nakata, and M. Mori et al. Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma Leuk Res 35 2011 787 792
21. K. Yamanaka, T. Nakahara, T. Yamauchi, A. Kita, M. Takeuchi, and F. Kiyonaga et al. Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models Clin Cancer Res 17 2011 5423 5431
22. T. Nakahara, K. Yamanaka, S. Hatakeyama, A. Kita, M. Takeuchi, and I. Kinoyama et al. YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model Anticancer Drugs 22 2011 454 462
23. T. Iwasa, I. Okamoto, K. Takezawa, K. Yamanaka, T. Nakahara, and A. Kita et al. Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs Br J Cancer 103 2010 36 42
24. A. Kita, K. Mitsuoka, N. Kaneko, M. Nakata, K. Yamanaka, and M. Jitsuoka et al. Sepantronium bromide (YM155) enhances response of human B-cell non-Hodgkin lymphoma to rituximab J Pharmacol Exp Ther 343 2012 178 183
25. B. Kumar, A. Yadav, J.C. Lang, M.J. Cipolla, A.C. Schmitt, and N. Arradaza et al. YM155 reverses cisplatin resistance in head and neck cancer by decreasing cytoplasmic survivin levels Mol Cancer Ther 11 2012 1988 1998
26. A.W. Tolcher, D.I. Quinn, A. Ferrari, F. Ahmann, G. Giaccone, and T. Drake et al. A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer Ann Oncol 23 2012 968 973
27. T. Iwasa, I. Okamoto, M. Suzuki, T. Nakahara, K. Yamanaka, and E. Hatashita et al. Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines Clin Cancer Res 14 2008 6496 6504
28. J. Rosa, P. Canovas, A. Islam, D.C. Altieri, and S.J. Doxsey Survivin modulates microtubule dynamics and nucleation throughout the cell cycle Mol Biol Cell 17 2006 1483 1493
29. D. Dai, Y. Liang, Z. Xie, J. Fu, Y. Zhang, and Z. Zhang Survivin deficiency induces apoptosis and cell cycle arrest in HepG2 hepatocellular carcinoma cells Oncol Rep 27 2012 621 627
30. A. Villunger, E.M. Michalak, L. Coultas, F. Mullauer, G. Bock, and M.J. Ausserlechner et al. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa Science 302 2003 1036 1038
31. K.K. Wong, D.I. Izaguirre, S.Y. Kwan, E.R. King, M.T. Deavers, and A.K. Sood et al. Poor survival with wild-type TP53 ovarian cancer? Gynecol Oncol 130 2013 565 569
32. A. Chakravarti, G.G. Zhai, M. Zhang, R. Malhotra, D.E. Latham, and M.A. Delaney et al. Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms Oncogene 23 2004 7494 7506
33. F. Rodel, J. Hoffmann, L. Distel, M. Herrmann, T. Noisternig, and T. Papadopoulos et al. Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer Cancer Res 65 2005 4881 4887